MDT
Medtronic PLC
NYSE: MDT · HEALTHCARE · MEDICAL DEVICES
$96.54
-0.59% today
Updated 2026-10-30
Market cap
$123.49B
P/E ratio
23.72
P/S ratio
3.29x
EPS (TTM)
$4.07
Dividend yield
2.93%
52W range
$72 – $103
Volume
19.2M
WallStSmart proprietary scores
68
out of 100
Grade: B
Buy
Investment rating
7.3
Growth
B+6.5
Quality
B6.5
Profitability
B4.7
Valuation
C5/9
Piotroski F-Score
Moderate
2.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$108.89
+12.79%
12-Month target
$77.52
-19.70%
Intrinsic (DCF)
$94.08
Margin of safety
-2.61%
3 Strong Buy16 Buy9 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $1.29B — positive
+ Revenue growth 13.70% QoQ
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM | 2027 (E) |
|---|---|---|---|---|---|---|
| Revenue | $31.23B | $32.36B | $33.54B | $36.36B | $37.54B | $39.0B |
| Net income | $3.76B | $3.68B | $4.66B | $4.80B | $1.47B | — |
| EPS | — | — | — | — | $4.07 | $6.14 |
| Free cash flow | $4.58B | $5.20B | $5.18B | $5.43B | $1.29B | — |
| Profit margin | 12.03% | 11.36% | 13.90% | 13.20% | 13.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-10-15 | MEDTRONIC, PLC | J | 252,813,348 | — |
| 2026-10-15 | MARTHA, GEOFFREY | S | 50,000 | $95.00 |
| 2026-10-15 | MARINARO, MICHAEL | S | 10,420 | $96.00 |
Peer comparison
Smart narrative
Medtronic PLC trades at $96.54. representing a P/E of 23.72x trailing earnings. Our Smart Value Score of 68/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 1.99, it sits in the grey zone. TTM revenue stands at $37.54B. with profit margins at 13.90%. Our DCF model estimates intrinsic value at $94.08.
Frequently asked questions
What is Medtronic PLC's stock price?
Medtronic PLC (MDT) trades at $96.54, on a P/E of 23.7x and a P/S of 3.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Medtronic PLC overvalued?
Medtronic PLC carries a Smart Value Score of 68/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $94.08 against the $96.54 price, so on cash flow terms the market is paying a premium for Medtronic PLC's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Medtronic PLC (MDT)?
The 12-month analyst consensus target is $108.89, about 12.8% above the current $96.54. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of MDT by 2030?
Our research-backed model puts the 2030 base case at $441.81, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Medtronic PLC (MDT)?
Our DCF model estimates intrinsic value at $94.08, a -2.6% margin of safety versus today's $96.54. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Medtronic PLC's revenue?
Medtronic PLC's trailing twelve-month revenue is $37.54B, and our model projects it reaching about $46.89B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Medtronic PLC's Altman Z-Score is 1.99, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.29x
ROE10.41%
Beta0.57
50D MA$91.70
200D MA$88.16
Shares out1.28B
Float1.28B
Short ratio—
Avg volume19.2M
Performance
1 week+1.85%
1 month+11.76%
3 months+11.38%
YTD+0.50%
1 year+6.44%
3 years—
5 years—